早期应用β受体阻滞剂对慢性心力衰竭患者心脏功能的影响  

Effects of Early Application of β-adrenocepter Antagonistson Cardiac Function on Patients with Chronic Heart Failure

作　　者：陈祥坤 沈学谦[2] 郭宏[2] 程洪箴[3] 马运伟[2] 司福中[2] 

机构地区：[1]山东省武所屯生建煤矿医院内科,山东滕州277521 [2]山东省滕州市中心人民医院特殊检查科,山东滕州277500 [3]山东省滕州市中心人民医院化验室,山东滕州277500

出　　处：《医学综述》2009年第16期2522-2524,共3页Medical Recapitulate

摘　　要：目的探讨早期应用美托洛尔缓释片对慢性心力衰竭患者心脏功能的影响。方法将76例纽约心脏病协会（NYHA）心脏功能分级Ⅱ～Ⅳ级的慢性心力衰竭患者随机分为治疗组（38例）和对照组（38例），两组均给予常规内科治疗，治疗组早期加用美托洛尔缓释片；对照组待症状好转（能平卧可室内活动）、水肿达轻度或消失后加用美托洛尔缓释片，总疗程均为3个月。观察两组治疗前后NYHA心脏功能分级、心功能恶化及治疗期间病死人数，以及心脏功能相关指标的变化。结果治疗组治疗后心脏功能NYHA分级、左室射血分数、血浆B型脑利钠利尿肽水平及6 min步行距离明显优于对照组（P〈0.05）；心功能恶化及治疗期间死亡人数明显低于对照组。结论早期合理应用美托洛尔缓释片能改善慢性心力衰竭患者心脏功能并且安全可行。Objective To investigate the effects of metoprolol sueeinate sustained-release tablets on eardiae funetion in patients with chronic heart failure（CHF）. Methods A total of 76 patients with CHF were di- vided randomly into a treatment group（38 eases） and a control group（38 cases）. On the basis of routine pharmacotheraphy, both groups were given metoprolol tartrate sustained-release tablets for 3 months. The therapy in the treatment group was given in the early period, while in the control group, after remission. The New York Heart Association（NYHA） cardiac function grading system and died eases during treatment as well as cardiac function related indite of the two groups were observed before and after treatment. Results After treatment, NYHA cardiac function grading, left ventricle ejection fraction （LVEF） , BNP in plasma and 6 mln walking range in the treatment group were markedly superior to those in the control group（P 〈0.05）. while the number of death was obviously lower （ P 〈 0.05 ）. Conclusion The early rational application of metoprolol tartrate sustaine-release tablets can not only improve the eardiae function of patients with CHF but also was safe and feasible.

关 键 词：慢性心力衰竭 血浆B型脑利钠利尿肽 左室射血分数 美托洛尔缓释片 

分 类 号：R541.6[医药卫生—心血管疾病]